Arcticzymes Technologies ASA - Asset Resilience Ratio

Latest as of December 2025: 21.29%

Arcticzymes Technologies ASA (AZT) has an Asset Resilience Ratio of 21.29% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Nkr76.94 Million
≈ $8.10 Million USD Cash + Short-term Investments

Total Assets

Nkr361.41 Million
≈ $38.03 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Arcticzymes Technologies ASA's Asset Resilience Ratio has changed over time. Check Arcticzymes Technologies ASA strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Arcticzymes Technologies ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Arcticzymes Technologies ASA.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Nkr0.00 0%
Short-term Investments Nkr76.94 Million 21.29%
Total Liquid Assets Nkr76.94 Million 21.29%

Asset Resilience Insights

  • Good Liquidity Position: Arcticzymes Technologies ASA maintains a healthy 21.29% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Arcticzymes Technologies ASA Industry Peers by Asset Resilience Ratio

Compare Arcticzymes Technologies ASA's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
argenx NV ADR
NASDAQ:ARGX
Biotechnology 10.93%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
Biotechnology 5.07%
Amicus Therapeutics Inc
NASDAQ:FOLD
Biotechnology 8.37%
Sk Biopharmaceuticals Co Ltd
KO:326030
Biotechnology 0.14%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%

Annual Asset Resilience Ratio for Arcticzymes Technologies ASA (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Arcticzymes Technologies ASA.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 21.29% Nkr76.94 Million
≈ $8.10 Million
Nkr361.41 Million
≈ $38.03 Million
-49.57pp
2024-12-31 70.86% Nkr243.94 Million
≈ $25.67 Million
Nkr344.26 Million
≈ $36.23 Million
+17.55pp
2023-12-31 53.31% Nkr180.89 Million
≈ $19.04 Million
Nkr339.32 Million
≈ $35.71 Million
-23.22pp
2022-12-31 76.53% Nkr244.16 Million
≈ $25.69 Million
Nkr319.04 Million
≈ $33.57 Million
+5.99pp
2021-12-31 70.54% Nkr200.42 Million
≈ $21.09 Million
Nkr284.11 Million
≈ $29.90 Million
+7.38pp
2020-12-31 63.17% Nkr140.18 Million
≈ $14.75 Million
Nkr221.91 Million
≈ $23.35 Million
+22.85pp
2019-12-31 40.32% Nkr31.29 Million
≈ $3.29 Million
Nkr77.61 Million
≈ $8.17 Million
-6.24pp
2018-12-31 46.55% Nkr31.66 Million
≈ $3.33 Million
Nkr68.02 Million
≈ $7.16 Million
-3.05pp
2017-12-31 49.60% Nkr30.59 Million
≈ $3.22 Million
Nkr61.68 Million
≈ $6.49 Million
-17.60pp
2016-12-31 67.19% Nkr57.67 Million
≈ $6.07 Million
Nkr85.83 Million
≈ $9.03 Million
--
pp = percentage points

About Arcticzymes Technologies ASA

OL:AZT Norway Biotechnology
Market Cap
$106.41 Million
Nkr1.01 Billion NOK
Market Cap Rank
#18932 Global
#169 in Norway
Share Price
Nkr19.80
Change (1 day)
+1.28%
52-Week Range
Nkr17.85 - Nkr30.90
All Time High
Nkr111.00
About

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal… Read more